Detalles de la búsqueda
1.
Tafasitamab mediates killing of B-cell non-Hodgkin's lymphoma in combination with γδ T cell or allogeneic NK cell therapy.
Cancer Immunol Immunother
; 71(11): 2829-2836, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-35348812
2.
A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.
J Biol Chem
; 289(27): 18693-706, 2014 Jul 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-24841203
3.
Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.
Arch Biochem Biophys
; 526(2): 206-18, 2012 Oct 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-22464987
4.
A human cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM overexpressing tumor cells.
Cancer Immun
; 6: 4, 2006 Feb 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-16483188
5.
XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer.
MAbs
; 8(4): 811-27, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26984378
6.
Antitumor activity of a dual cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM expressing tumor cells.
J Immunother
; 29(5): 477-88, 2006.
Artículo
en Inglés
| MEDLINE | ID: mdl-16971804
Resultados
1 -
6
de 6
1
Próxima >
>>